Austral Capital
No summary available yet.
Austral Capital is essentially a one-person show built around Gonzalo Miranda's extensive Chilean business network. Miranda's Endeavor background gives him serious founder credibility, but this fund has been notably quiet for a decade - their "latest" portfolio company data from most sources is 2012-2015. The recent Zonox investment in late 2024 suggests they're back in action, but with just $200M AUM over 16 years and two exits in 2022, this feels more like a boutique family office than an active VC. The Warburg Pincus exit shows they can deliver returns, but founders should expect a very hands-on, network-heavy approach typical of smaller regional funds. Good for Chilean founders who value deep local connections over fast capital deployment.
- —Best for: Chilean B2B founders wanting deep local networks and patient capital
- —Watch out for: Limited recent investment activity and small team capacity
- —Known for: Successful exits to strategic buyers and strong entrepreneurship ecosystem ties
Austral Capital focuses on identifying globally scalable, high-growth technology entrepreneurs in Latin America, particularly in biotech and information technology. They emphasize backing companies that can catalyze regional transformation in retail, banking, fintech, and health sectors through technology-enabled solutions.
Targets $1-5M investments in early to growth-stage B2B companies, with sweet spot around $2.5M. Portfolio spans fintech (Multicaja/Klap), retail tech (Scanntech), biotech (Andes Biotechnologies), and data/SaaS companies. Despite claiming biotech focus, actual portfolio leans heavily technology services and fintech.
Kauffman Fellow with UC Berkeley MBA/MOT and mechanical engineering background. Former Managing Director at Endeavor Chile and ex-corporate development at Canal 13. Teaches entrepreneurship at Universidad Católica de Chile and sits on multiple boards including Chilean VC association ACAFI.
Have a specific question about Austral Capital?
Ask Bernie →